106006-83-1

Basic information

• Product Name: 2,6-Diamino-4,5,6,7-tetrahydrobenzothiazole
• Synonyms: ()-2,6-DIAMINO-4,5,6,7-TETRA-HYDROBENZOTHIAZOL;4,5,6,7-tetrahydrothieno[3,4-c]pyridine-1,3-diamine;R,S-2,6-DiaMino-4,5,6,7- tetrahydrobenzothiazole
• CAS NO: 106006-83-1
• Molecular Formula: C₇H₁₁N₃S
• Molecular Weight: 169.25
• Mol File: 106006-83-1.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 359 °C at 760 mmHg
• Flash Point: 170.9 °C
• Appearance: off-white powder
• Density: 1.313 g/cm³
• Vapor Pressure: 2.45E-05mmHg at 25°C
• Refractive Index: 1.655
• CAS DataBase Reference: 2,6-Diamino-4,5,6,7-tetrahydrobenzothiazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-Diamino-4,5,6,7-tetrahydrobenzothiazole(106006-83-1)
• EPA Substance Registry System: 2,6-Diamino-4,5,6,7-tetrahydrobenzothiazole(106006-83-1)

Safety Data

• Hazardous Substances Data: 106006-83-1(Hazardous Substances Data)

Usage

General Description

2,6-Diamino-4,5,6,7-tetrahydrobenzothiazole is a chemical compound with the molecular formula C7H11N3S. It is an organic compound composed of a benzothiazole ring with two amino groups attached to the 2 and 6 positions. This chemical has been studied for its potential use as a precursor or intermediate in the synthesis of pharmaceuticals and organic compounds. It is also known for its potential applications in the field of chemistry and materials science. 2,6-Diamino-4,5,6,7-tetrahydrobenzothiazole has been the subject of research due to its interesting chemical and biological properties, and its potential use in various industrial applications.

InChI:InChI=1/C7H11N3S/c8-4-1-2-5-6(3-4)11-7(9)10-5/h4H,1-3,8H2,(H2,9,10)

Upstream product

• 104617-50-7 N-(2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)acetamide hydrobromide 
• 104618-33-9 2-(2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)isoindoline-1,3-dione 
• 916334-22-0 2-Amino-6-phthalimido-4,5,6,7-tetrahydrobenzothiazole hydroiodide 
• 113030-24-3 2-amino-6-oxo-4,5,6,7-tetrahydrobenzothiazole 
• 17356-08-0 thiourea 
• 27489-62-9 trans-4-aminocyclohexan-1-ol 
• 766508-72-9 2-bromo-4-aminocyclohexanone 
• 27514-08-5 N-(4-oxocyclohexyl)acetamide 
• 106006-80-8 N-(2-amino-4,5,6,7-tetrahydrobenzo[1,2-d]thiazol-6-yl)acetamide 
• 687639-03-8 2-bromo-4-acetamidocyclohexanone 
• 23363-88-4 trans-N-acetyl-4-hydroxycyclohexylamine 
• 202058-46-6 2-(3-bromo-4-oxocyclohexyl)isoindoline-1,3-dione 
• 27489-62-9 trans-4-hydroxycyclohexylamine 
• 104618-32-8 2-(4-oxocyclohexyl)-1H-isoindole-1,3(2H)-dione 

Downstream Products

• 104617-86-9 2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole 
• 820231-27-4 tert-butyl (2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)carbamate 
• 104632-25-9 pramipexole dihydrochloride 
• 1262552-32-8 1-((S)-2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-3-(2-chlorophenyl)thiourea 
• 1262552-33-9 1-((S)-2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-3-(2,4-dichlorophenyl)thiourea 
• 1262552-34-0 1-((S)-2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-3-(4-chlorophenyl)thiourea 
• 1262552-35-1 1-((S)-2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-3-phenylthiourea 
• 1262552-27-1 1-((S)-2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-3-(4-methoxyphenyl)thiourea 
• 1262552-28-2 1-((S)-2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-3-(4-fluorophenyl)thiourea 
• 1262552-29-3 1-((S)-2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-3-(3-chlorophenyl)thiourea 
• 1262552-30-6 1-((S)-2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-3-(3-methoxyphenyl)thiourea 
• 1262552-31-7 1-((S)-2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-3-(2-fluorophenyl)thiourea 
• 106006-84-2 (S)?2?amino?6?propionamido?4,5,6,7?tetrahydrobenzothiazole 
• 106006-85-3 (+)-2-amino-6-propionamidotetrahydrobenzothiazole 

Relevant articles and documents

Pharmacological characterization of a new series of carbamoylguanidines reveals potent agonism at the H2R and D3R

Even today, the role of the histamine H2 receptor (H2R) in the central nervous system (CNS) is widely unknown. In previous research, many dimeric, high-affinity and subtype-selective carbamoylguanidine-type ligands such as UR-NK22 (5, pKi = 8.07) were reported as H2R agonists. However, their applicability to the study of the H2R in the CNS is compromised by their molecular and pharmacokinetic properties, such as high molecular weight and, consequently, a limited bioavailability. To address the need for more drug-like H2R agonists with high affinity, we synthesized a series of monomeric (thio)carbamoylguanidine-type ligands containing various spacers and side-chain moieties. This structural simplification resulted in potent (partial) agonists (guinea pig right atrium, [35S]GTPγS and β-arrestin2 recruitment assays) with human (h) H2R affinities in the one-digit nanomolar range (pKi (139, UR-KAT523): 8.35; pKi (157, UR-MB-69): 8.69). Most of the compounds presented here exhibited an excellent selectivity profile towards the hH2R, e.g. 157 being at least 3800-fold selective within the histamine receptor family. The structural similarities of our monomeric ligands to pramipexole (6), a dopamine receptor agonist, suggested an investigation of the binding behavior at those receptors. The target compounds were (partial) agonists with moderate affinity at the hD2longR and agonists with high affinity at the hD3R (e.g. pKi (139, UR-KAT523): 7.80; pKi (157, UR-MB-69): 8.06). In summary, we developed a series of novel, more drug-like H2R and D3R agonists for the application in recombinant systems in which either the H2R or the D3R is solely expressed. Furthermore, our ligands are promising lead compounds in the development of selective H2R agonists for future in vivo studies or experiments utilizing primary tissue to unravel the role and function of the H2R in the CNS.

Crystallization process of diamino -4, 5, 6, 7- tetrahydrobenzothiazole

Reaction and formation, of the product, with acetone as a reaction solvent, takes place in acetone as a reaction solvent to give the product, as a raw material, with acetone as a reaction solvent to obtain the mixed rotation product, and then recrystallize the reaction solvent with water: to obtain the reaction . Example, shows that the reaction time, is greatly shortened by taking the product, as a reaction solvent by taking acetone as a reaction solvent as a raw material A; dropwise to obtain the reaction and the reaction of the reaction, solvent with water and dissolving: dropwise with acetone as a reaction solvent in step A as a reaction solvent in an existing production process by, acetone, L - taking acetone as a, reaction solvent to prepare a reaction solvent for, the whole process, to prepare a crystal, by taking acetone as, a reaction solvent to prepare a reaction solvent by taking acetone as a reaction solvent to prepare a. reaction solvent by taking acetone as a reaction solvent.

Preparation method of pramipexole dihydrochloride and intermediate thereof

The invention discloses a preparation method of pramipexole dihydrochloride and an intermediate thereof. The invention provides a preparation of pramipexole II. The preparation method of the pramipexole II comprises the following steps: performing condensation reaction and reduction reaction on a pramipexole intermediate III, propylamine and hydrogen in an organic solvent and under the existence of a chiral catalyst, and performing one-pot method to obtain the pramipexole II. According to the preparation method provided by the invention, the route step is short, chiral resolution is not neededand the total molar yield is high; furthermore, the prepared product has high purity, can reach to the standard of raw material medicines and is suitable for industrialized production. (The formula is shown in the description).